Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 May;37(5):1001–1003. doi: 10.1128/aac.37.5.1001

Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.

S Y Tsui 1, W W Yew 1, M S Li 1, C Y Chan 1, A F Cheng 1
PMCID: PMC187877  PMID: 8517688

Abstract

A study of postantibiotic effects (PAE) in vitro of amikacin and ofloxacin on Mycobacterium fortuitum isolates from sternotomy wounds by use of the dilution method for drug removal showed that both drugs exhibited good bactericidal activities, with the PAE of amikacin lasting from 13.5 to 27.6 h and the PAE of ofloxacin lasting from 1.2 to 5.0 h. These laboratory results concur with our experience of the efficacy of once-daily dosing with these drugs in the treatment of infections caused by M. fortuitum. These data may have therapeutic implications in guiding the scheduling of the administration of drugs in these infections, which require a long duration of therapy.

Full text

PDF
1001

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bundtzen R. W., Gerber A. U., Cohn D. L., Craig W. A. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981 Jan-Feb;3(1):28–37. doi: 10.1093/clinids/3.1.28. [DOI] [PubMed] [Google Scholar]
  2. Dall L., Long L., Stanford J. Poncet's disease: tuberculous rheumatism. Rev Infect Dis. 1989 Jan-Feb;11(1):105–107. doi: 10.1093/clinids/11.1.105. [DOI] [PubMed] [Google Scholar]
  3. Dalovisio J. R., Pankey G. A. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin. J Infect Dis. 1978 Mar;137(3):318–321. doi: 10.1093/infdis/137.3.318. [DOI] [PubMed] [Google Scholar]
  4. Dickinson J. M., Mitchison D. A. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle. 1970 Dec;51(4):389–396. doi: 10.1016/0041-3879(70)90004-8. [DOI] [PubMed] [Google Scholar]
  5. Kunin C. M. Dosage schedules of antimicrobial agents: a historical review. Rev Infect Dis. 1981 Jan-Feb;3(1):4–11. doi: 10.1093/clinids/3.1.4. [DOI] [PubMed] [Google Scholar]
  6. McDonald P. J., Craig W. A., Kunin C. M. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis. 1977 Feb;135(2):217–223. doi: 10.1093/infdis/135.2.217. [DOI] [PubMed] [Google Scholar]
  7. Mitchison D. A., Dickinson J. M. Laboratory aspects of intermittent drug therapy. Postgrad Med J. 1971 Nov;47(553):737–741. doi: 10.1136/pgmj.47.553.737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Renneberg J., Walder M. Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo. Antimicrob Agents Chemother. 1989 Oct;33(10):1714–1720. doi: 10.1128/aac.33.10.1714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Swenson J. M., Wallace R. J., Jr, Silcox V. A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec;28(6):807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Texier-Maugein J., Mormède M., Fourche J., Bébéar C. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria. Eur J Clin Microbiol. 1987 Oct;6(5):584–586. doi: 10.1007/BF02014255. [DOI] [PubMed] [Google Scholar]
  11. Todd P. A., Faulds D. Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs. 1991 Nov;42(5):825–876. doi: 10.2165/00003495-199142050-00008. [DOI] [PubMed] [Google Scholar]
  12. Vogelman B. S., Craig W. A. Postantibiotic effects. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):37–46. doi: 10.1093/jac/15.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  13. Welch D. F., Kelly M. T. Antimicrobial susceptibility testing of Mycobacterium fortuitum complex. Antimicrob Agents Chemother. 1979 Jun;15(6):754–757. doi: 10.1128/aac.15.6.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yew W. W., Kwan S. Y., Ma W. K., Aung-khin M., Mok C. K. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection. Chest. 1989 May;95(5):1051–1055. doi: 10.1378/chest.95.5.1051. [DOI] [PubMed] [Google Scholar]
  15. Yew W. W., Kwan S. Y., Ma W. K., Khin M. A., Mok C. K. Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection. Chest. 1989 Nov;96(5):1150–1152. doi: 10.1378/chest.96.5.1150. [DOI] [PubMed] [Google Scholar]
  16. Yew W. W., Kwan S. Y., Ma W. K., Lui K. S., Aung M. K. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds. Clin Ther. 1989 Nov-Dec;11(6):775–785. [PubMed] [Google Scholar]
  17. Yew W. W., Kwan S. Y., Ma W. K., Lui K. S., Suen H. C. Ofloxacin therapy of Mycobacterium fortuitum infection: further experience. J Antimicrob Chemother. 1990 May;25(5):880–881. doi: 10.1093/jac/25.5.880. [DOI] [PubMed] [Google Scholar]
  18. Yew W. W., Kwan S. Y., Wong P. C., Lee J. Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle. 1990 Jun;71(2):131–133. doi: 10.1016/0041-3879(90)90009-w. [DOI] [PubMed] [Google Scholar]
  19. Young L. S., Berlin O. G., Inderlied C. B. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987 Apr 27;82(4A):23–26. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES